We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Patients who were treated with Biogen Idec and Elan’s multiple-sclerosis drug Tysabri displayed no new cases of progressive multifocal leukoencephalopathy (PML), a rare and deadly nerve disease that has been linked to the drug, an NIH study found.
The FDA's Janus project to populate a cross-trial database has made some "exciting progress," yet much remains to be done, said experts at a Drug Information Association (DIA) webinar March 2.
The FDA approved Erbitux (cetuximab) for use in combination with radiation therapy to treat patients with squamous cell cancer of the head and neck (SCCHN) that can not be removed by surgery.
Using two dietary supplements — glucosamine HCl and chondroitin sulfate — relieves moderate-to-severe osteoarthritis pain better than celecoxib, according to an NIH-sponsored study published in the New England Journal of Medicine (NEJM).
The Association of American Medical Colleges (AAMC) examined the recommendations published in last month’s Journal of the American Medical Association aimed at minimizing the potentially adverse influence of gifts and other blandishments from drug and medical device makers on the missions of academic medical centers.
Sharing clinical trial outcomes with participants may do more harm than good, argues an oncologist with the University of Texas' M.D. Anderson Cancer Center.
Drugs given to patients prior to emergency heart attack surgery may do more harm than good, according to a study recently published in a major journal.
Unfavorable outcomes prompted the California biotech firm InterMune to halt its Phase III trial of Actimmune (interferon gamma-1b), a chemotherapy adjunct, the company announced Feb. 2.